Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation

Caliskan Y., Besisik S., Sargin D., Ecder T.

Bone Marrow Transplantation, vol.38, no.2, pp.141-147, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2006
  • Doi Number: 10.1038/sj.bmt.1705412
  • Journal Name: Bone Marrow Transplantation
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.141-147
  • Keywords: stem cell transplantation, renal dysfunction, sepsis, cyclosporine A, BONE-MARROW-TRANSPLANTATION, HIGH-DOSE CHEMOTHERAPY, VENOOCCLUSIVE DISEASE, FAILURE, NEPHROTOXICITY, DYSFUNCTION, RISK, MALIGNANCIES, GENTAMICIN, LIVER
  • Istanbul University Affiliated: Yes

Abstract

Renal insufficiency is a common complication early after hematopoietic stem cell transplantation ( HSCT). Renal function as measured by creatinine clearance (CrCl) was prospectively evaluated in 47 patients undergoing allogeneic (n = 22) or autologous (n = 25) HSCT during the first 100 days. Renal dysfunction was classified as follows: Grade 0 (< 25% decline in CrCl), Grade 1 (>= 25% decline in CrCl but < 2 x increase in serum creatinine), Grade 2 (>= 2 x rise in serum creatinine but no need for dialysis) and Grade 3 (>= 2 x rise in serum creatinine and need for dialysis). Thirty-three patients (70%) had Grade 1-3 renal dysfunction. Renal dysfunction was more common after myeloablative allogeneic HSCT (91%) than autologous HSCT (52%) (P = 0.004), and was associated with a high risk of mortality (P = 0.039). Sepsis in autologous HSCT patients and cyclosporine toxicity in allogeneic HSCT patients were associated with renal dysfunction. We conclude that autologous and allogeneic HSCT differ in the likelihood and causes of renal dysfunction.